Home › Basal Cell Carcinoma › NCT07010692
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Using Fractional Lasers and Tirbanibulin Ointment to Treat Keratinocyte Carcinomas
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: biopsy confirmed squamous and/or basal cell carcinoma not previously treated by another method. Exclusion Criteria: * Cannot be pregnant at the time of treatment
About the study
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.
What is being tested
- Tirbanibulin ointment 1% (drug)
- non-ablative fractional laser (device)
Sponsor: Bruce Robinson, MD · Participants: 100 · Started: May 16, 2025
Contact the study team
- Gillian Nanni, Research Coordinator, BS · Phone: 212-750-7121
Official record on ClinicalTrials.gov — NCT07010692
Locations in the U.S.
| New York | Bruce Robinson, MD, New York |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.